{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:26:57Z","timestamp":1786688817861,"version":"build-2736575974"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Classic juvenile pityriasis rubra pilaris (PRP) (Griffiths type III) is a rare inflammatory papulosquamous dermatosis that is often refractory to conventional topical and systemic treatments. Despite the growing use of tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors in adult PRP, clinical evidence for their efficacy and safety in children under 5 years remains extremely limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We herein report a 4-year-and-7-month-old Chinese girl presenting with a 20-day history of rapidly progressive generalized erythema, follicular keratotic papules, diffuse scaling, severe palmoplantar keratoderma and intractable pruritus. Initial differential diagnoses included psoriasis and pityriasis rubra pilaris (PRP), and skin histopathology confirmed classic juvenile PRP. Prior interventions with topical corticosteroids, emollients, oral antihistamines and traditional Chinese medicine yielded minimal clinical improvement. From the caregiver\u2019s perspective, persistent extensive cutaneous lesions with unremitting pruritus disrupted the child\u2019s daily activities, and multiple unsuccessful conventional therapies triggered considerable anxiety regarding long-term disease management. Given disease refractoriness, off-label adalimumab therapy was initiated. The patient received subcutaneous adalimumab at an initial dose of 20 mg at week 0, followed by 20 mg at week 1, and subsequent maintenance doses of 20 mg every two weeks, with a total of 8 injections. Approximately 3 months after treatment initiation, all cutaneous lesions achieved complete resolution, with only residual hypopigmented macules observed. No severe adverse events occurred during the treatment course. At the latest follow-up, 8 months after the final adalimumab injection, the patient maintained sustained complete remission without relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This clinical case demonstrates that adalimumab achieves rapid therapeutic efficacy and favorable short-term safety in young children with refractory classic juvenile PRP. Our findings support the potential role of TNF-\u03b1 inhibitors as an effective alternative for severe pediatric PRP unresponsive to conventional therapies. Further prospective controlled trials are warranted to validate the long-term safety profile and optimize the dosage regimen for young pediatric populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1885641","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:32:05Z","timestamp":1786685525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of refractory classic juvenile pityriasis rubra pilaris with adalimumab in a 4-year-old girl: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Jianlan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Wuhan No. 1 Hospital","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province & Key Laboratory of Skin Infection And Immunity, Hubei Provincial Clinical Research Center for Infectious Skin Diseases","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyue","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuhan No. 1 Hospital","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province & Key Laboratory of Skin Infection And Immunity, Hubei Provincial Clinical Research Center for Infectious Skin Diseases","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruili","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuhan No. 1 Hospital","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province & Key Laboratory of Skin Infection And Immunity, Hubei Provincial Clinical Research Center for Infectious Skin Diseases","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuhan No. 1 Hospital","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province & Key Laboratory of Skin Infection And Immunity, Hubei Provincial Clinical Research Center for Infectious Skin Diseases","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuhan No. 1 Hospital","place":["Wuhan, Hubei, China"]},{"name":"Hubei Province & Key Laboratory of Skin Infection And Immunity, Hubei Provincial Clinical Research Center for Infectious Skin Diseases","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.056","article-title":"Pityriasis rubra pilaris","volume":"92","author":"Sagut","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124619","article-title":"Pityriasis rubra pilaris in children","volume":"47","author":"Allison","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00836-x","article-title":"Pityriasis rubra pilaris: An updated review of clinical presentation, etiopathogenesis, and treatment options","volume":"25","author":"Joshi","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2165\/11531820-000000000-00000","article-title":"Pityriasis rubra pilaris: A review of diagnosis and treatment","volume":"11","author":"Klein","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-022-00549-4","article-title":"Treatment options for juvenile pityriasis rubra pilaris","volume":"25","author":"Guenther","year":"2023","journal-title":"Paediatr Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.09.010","article-title":"Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl","volume":"4","author":"Bonomo","year":"2018","journal-title":"JAAD Case Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241238735","article-title":"Biologics for treatment of pityriasis rubra pilaris: A literature review","volume":"28","author":"Chandy","year":"2024","journal-title":"J Cutan Med Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18029","article-title":"Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis","volume":"181","author":"Tha\u00e7i","year":"2019","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2498-1","article-title":"Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years","volume":"33","author":"Kingsbury","year":"2014","journal-title":"Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13038","article-title":"Clinical remission of pityriasis rubra pilaris with adalimumab in an adolescent patient","volume":"42","author":"Kim","year":"2015","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15965","article-title":"Classical juvenile pityriasis rubra pilaris treated with secukinumab: Case report and a review of biological treatments in the pediatric population","volume":"42","author":"Fratton","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado2365","article-title":"Targeting IL-1 controls refractory pityriasis rubra pilaris","volume":"10","author":"Schmauch","year":"2024","journal-title":"Sci Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.12788\/cutis.1096","article-title":"Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab and acitretin","volume":"114","author":"Khalil","year":"2024","journal-title":"Cutis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.09.010","article-title":"Biologic therapy for pediatric pityriasis rubra pilaris","volume":"12","author":"Bonomo","year":"2018","journal-title":"J Dermatol Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.05.042","article-title":"Safety of adalimumab in pediatric patients with inflammatory autoimmune diseases","volume":"201","author":"Horneff","year":"2018","journal-title":"J Pediatr"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1885641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:32:06Z","timestamp":1786685526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1885641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2026.1885641"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1885641","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1885641"}}